- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC's stock jumps after Q1 report
ADAC Laboratories of Milpitas, CA, pleased the investment communitylast week by announcing that it expects sharply higher bookingsand revenue for its first quarter of fiscal 1996 (end-December).The market responded by sending the nuclear medicine
ADAC Laboratories of Milpitas, CA, pleased the investment communitylast week by announcing that it expects sharply higher bookingsand revenue for its first quarter of fiscal 1996 (end-December).The market responded by sending the nuclear medicine vendor'sstock up 19% to close at $14.13 a share on Jan. 10, a 52-weekhigh.
ADAC said that it expects first-quarter revenues of $54 millionto $55 million, a 24% increase over last year's sales of $44 million.Earnings per share will be about 20¢ versus 15¢ in thesame period last year. Nuclear medicine bookings skyrocketed 61%to $48 million.
In a presentation last week at the Hambrecht & Quist HealthCare Conference in San Francisco, ADAC CEO David Lowe said thecompany's Molecular Coincidence Detection (MCD) technology isdriving new sales and will enable the company to take market sharefrom other vendors and other modalities.
"Over time, (MCD) has the potential not only to improveour market share in our core business, but more importantly todrive additional market opportunities for our core business aswe replace conventional imaging in the staging of cancer patients,"Lowe said.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
